Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers

Background Hydroxychloroquine (HCQ) is a widely prescribed medication to patients with systemic lupus erythematosus (SLE), with potential anti-inflammatory effects. This study was performed to investigate the efficacy of HCQ therapy by serial assessment of disease activity and serum levels of proinf...

Full description

Saved in:
Bibliographic Details
Published in:Inflammopharmacology 2018-10, Vol.26 (5), p.1175-1182
Main Authors: Monzavi, Seyed Mostafa, Alirezaei, Aida, Shariati-Sarabi, Zhaleh, Tavakol Afshari, Jalil, Mahmoudi, Mahmoud, Dormanesh, Banafsheh, Jahandoost, Faezeh, Khoshdel, Ali Reza, Etemad Rezaie, Ali
Format: Article
Language:English
Subjects:
Adult
Allergology
Antibodies, Antinuclear - immunology
Antirheumatic Agents - therapeutic use
Biomarkers - metabolism
Biomedical and Life Sciences
Biomedicine
Case-Control Studies
Cohort Studies
Cytokines - blood
Dermatology
Female
Follow-Up Studies
Gastroenterology
Humans
Hydroxychloroquine - therapeutic use
Immunology
Interleukin-1beta - blood
Lupus Erythematosus, Systemic - drug therapy
Lupus Erythematosus, Systemic - immunology
Lupus Erythematosus, Systemic - physiopathology
Original Article
Pharmacology/Toxicology
Prospective Studies
Rheumatology
Treatment Outcome
Tumor Necrosis Factor-alpha - blood
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Hydroxychloroquine (HCQ) is a widely prescribed medication to patients with systemic lupus erythematosus (SLE), with potential anti-inflammatory effects. This study was performed to investigate the efficacy of HCQ therapy by serial assessment of disease activity and serum levels of proinflammatory cytokines in SLE patients. Methods In this prospective cohort study, 41 newly diagnosed SLE patients receiving 400 mg HCQ per day were included. Patients requiring statins and immunosuppressive drugs except prednisolone at doses lower than 10 mg/day were excluded. Outcome measures were assessed before commencement of HCQ therapy (baseline visit) as well as in two follow-up visits (1 and 2 months after beginning the HCQ therapy). Serum samples of 41 age-matched healthy donors were used as controls. Results Median levels of IL-1β ( p  
ISSN:0925-4692
1568-5608
DOI:10.1007/s10787-018-0512-y